Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit

Executive Summary

Regeneron’s five-year-old antibody partnership with Sanofi may be expensive, but it is starting to produce some interesting compounds in mid-to-late-stage clinical trials, with positive data to show.

You may also be interested in...



How And Why Genzyme And Alnylam Expanded Their Alliance

Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher sealed the deal.

How And Why Genzyme And Alnylam Expanded Their Alliance

Genzyme’s decision to deepen its alliance with Alnylam plays to the strategic needs of both parties and to their complementary strengths. The agreement also was helped by the companies’ physical proximity and by a high-level conversation between Maraganore and Viehbacher at a critical juncture.

Debate At PSA 2013: Can ‘Dream Team’ Approach To Scientific Innovation Work for Big Pharma?

How best to tap scientific innovation? Identifying the top ‘true’ innovators and nurturing them and their ideas in-house may work for biotechs like Regeneron, but the fruits of such efforts are too rare to be reliable growth engines for big companies like Pfizer. That’s one takeaway from a lively R&D chiefs debate at Elsevier’s PSA 2013.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel